eClinical Software: August 2009
The latest eclinical software in the clinical trials industry.
Planning and Analyzing Patient Recruitment
New module broadens planning and forecasting at site level
KMR Group (Chicago) has added a new module in its Enrollment Metrix Application called SiteView. SiteView offers users the ability to examine enrollment KPIs derived from site level data. The new module allows users to anticipate the expected number of patients to be recruited from any given site as well as the time it takes any given site to complete recruitment.
SiteView increases site knowledge
SiteView joins with the TrialView module, which both access KMR Group's industry data, which includes disease, phase, and geography obtained from over 100,000 sites from recently completed trials in the biopharmaceutical arena.
KMR Group, (312) 795-0400, http://kmrgroup.com
Randomization/Trial Supply Management
New reporting solution addresses timeline/supply in global trials
Perceptive Informatics (Boston) announced its new reporting solution as part of its ClinPhone Randomization and Trial Supply Management (RTSM) technologies, which offer validated randomization methods, automated inventory control, dispensing and titration management, and emergency code break capabilities.
Perceptive RTSM gains reporting tool
The reporting solution features a Universal Report Suite to monitor clinical trial management performance, RTSM Dashboard with trending and forecasting functions, and a Self-Service Module with customizable search criteria for in-depth data analysis.
Perceptive Informatics, (781) 487-9900, www.perceptive.com
Enhancements Address Diaries and Interactivity
Design tool offers added function and flexibility for clinical trials
CRF Health (Lansdale, PA) announces TrialMax 4.0, which extends its ePRO software suite function. The TrialMax eDiary design tool allows real-time development between study teams and trial sponsors. In addition, TrialMax 4.0 includes automated email notification and messaging, enhanced user account and password management, configurable data exports in a variety of output formats, report content export to Microsoft Excel, enhanced report printing, and configurable patient status icons.
Introducing TrialMax 4.0
TrialMax 4.0 has also been updated with new user interface graphics and the ability to embed links in study reports.
CRF Health, (267) 498-2300, www.crfhealth.com
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
April 28th 2025Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or recurrence in resectable, locally advanced head and neck squamous cell carcinoma, marking the first major clinical advance for this patient population in more than two decades.
